

Learn about a
clinical trial for
**ALZHEIMER'S
DISEASE
DEMENTIA**





What are clinical trials?

Clinical trials are research studies that help find out if investigational drugs are safe and if they can help prevent, find, or treat diseases or conditions.

Participant safety is the highest priority. There are rules in place to:

- Help protect the rights, safety, and well-being of people who volunteer to be in clinical trials
- Make sure that trials follow strict scientific and ethical guidelines

Before a clinical trial can begin, an Institutional Review Board (IRB) or Ethics Committee (EC) must review the clinical trial to ensure it follows regulations and ethical guidelines.

About this clinical trial

Researchers want to learn about an investigational drug in people with mild to moderate Alzheimer's disease dementia. This clinical trial is testing the safety of the investigational drug, MK-1167, and how well it may work when people take it with their current

Alzheimer's disease dementia medicine. MK-1167 is experimental. It has not been approved to treat or prevent Alzheimer's disease dementia or other conditions.

Who can take part in this clinical trial?

You may be able to take part in this trial if you are 55-90 years of age and:

- Have mild to moderate Alzheimer's disease dementia
- Are taking a cholinergic medicine for Alzheimer's disease dementia, such as donepezil, galantamine, or rivastigmine
- Have a trial partner/caregiver who can go with you to all trial visits and:
 - Knows you well
 - Is in regular contact with you
 - Can answer questions and surveys

The trial doctor will discuss more requirements to take part in this trial.

What drug will I get?

If you qualify and decide to join, you will be randomly assigned by a computer to take either the investigational drug, MK-1167, or the placebo. The placebo looks like the investigational drug but contains no active ingredients. This trial has 4 groups:

- **Groups 1, 2, and 3** will get MK-1167 and continue to get their Alzheimer's disease dementia treatment.
 - Each of these groups will get a different dose of MK-1167. The trial doctor or staff can give you more information about the MK-1167 doses.
- **Group 4** will get the placebo and continue to get their Alzheimer's disease dementia treatment.

You will have a 5-in-7 chance of being assigned to get the investigational drug and a 2-in-7 chance of receiving the placebo.

The investigational drug and placebo are both capsules. You will take the assigned capsule once each day by mouth during the 24-week trial treatment period.

What will happen during this clinical trial?

Taking part in the trial lasts about 10 months with at least 9 visits to the trial clinic. There are also at least 2 virtual visits with a member of the trial staff.

Medical tests include, but are not limited to, a physical exam, blood and urine samples, and an



electrocardiogram (ECG, a test that shows how well your heart is working). At the start of the trial, you will need to do brain imaging if you have not done so in the past year.

You will also be asked to answer questions or make drawings to measure how well you think, reason, remember, and make judgments. Your trial partner/caregiver will also answer questions and surveys.

If you decide to take part:

- You will get the trial drug, tests, and exams at no cost.
- Your Alzheimer's disease dementia symptoms and overall health will be checked and tracked by a trial doctor.
- You may help researchers learn more about Alzheimer's disease dementia and the investigational drug.

To learn more about this clinical trial, including the possible risks and benefits of joining, please contact:

